^
    2d
    Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models. (PubMed, Sci Rep)
    Significant leukemia load reductions in bone marrow, where disease originated, were also achieved in both responders (AM7577/AM8096), implicating that HX301 might be a potentially more effective therapy than those only affecting peripheral leukemic cells. Altogether, narazaciclib can potentially be a candidate treatment for a subset of AML with CSF1Rhi and/or mutant FLT3-ITD variants, particularly second generation FLT3 inhibitor resistant variants.
    Preclinical • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • CDK6 (Cyclin-dependent kinase 6) • CSF1R (Colony stimulating factor 1 receptor)
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 wild-type
    |
    narazaciclib (HX301)
    2d
    EvoPAR-BR01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, AstraZeneca
    New P3 trial • Metastases
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • camizestrant (AZD9833) • saruparib (AZD5305)
    2d
    CYCLHER: Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Apr 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    2d
    A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=550, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • HEOR • Combination therapy • Real-world evidence • Real-world • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib)
    3d
    ADELA: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (clinicaltrials.gov)
    P3, N=240, Not yet recruiting, MedSIR
    New P3 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation
    |
    everolimus • Orserdu (elacestrant)
    3d
    ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov)
    P3, N=3100, Suspended, Novartis Pharmaceuticals | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib) • letrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
    3d
    Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer. (PubMed, J Pharm Pract)
    Although the AEs of palbociclib and abemaciclib affected the treatment considerably, the treatment duration and RDI were similar. CDK4/6 inhibitors should be selected based on the tolerability and manageability of each AE.
    Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib)
    4d
    Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project. (PubMed, JCO Precis Oncol)
    We summarized the ctDNA and cancer tissue mutational landscape, including overall neoplastic burden and PIK3CA and ESR1 hotspot mutations in abemaciclib-treated patients with HR+/HER2- MBC. The data provide insights that could help optimize treatment strategies in this population.
    Journal • Circulating tumor DNA • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • FGF3 (Fibroblast growth factor 3) • GATA3 (GATA binding protein 3)
    |
    HR positive • HER-2 negative • PIK3CA mutation • ESR1 mutation • EGFR positive
    |
    Verzenio (abemaciclib)
    4d
    Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system. (PubMed, Eur J Health Econ)
    Despite the significant gains of abemaciclib as adjuvant treatment in terms of progression-free survival, this treatment is not cost-effective for the Spanish National Health System at published prices. It may be cost-effective with an appropriate discount on the official price.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib)
    4d
    The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, American Society of Clinical Oncology
    New P3 trial • Metastases
    |
    Ibrance (palbociclib) • Kisqali (ribociclib)
    4d
    Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=37, Recruiting, University of Washington | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Verzenio (abemaciclib)
    6d
    Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. (PubMed, Breast Cancer)
    The addition of palbociclib to ET was effective for treating HR+/HER2- ABC in Japanese routine clinical practice.
    Clinical • Observational data • Journal • Real-world evidence • Real-world • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Ibrance (palbociclib)
    7d
    Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics. (PubMed, J Clin Pharmacol)
    Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. Ad hoc analysis using National Cancer Institute classification showed similar results. The US Food and Drug Administration-approved trilaciclib dose of 240 mg/m2 should be reduced by ∼30%, to 170 mg/m2, for patients with moderate or severe HI.
    PK/PD data • Journal
    |
    CDK4 (Cyclin-dependent kinase 4)
    |
    etoposide IV • topotecan • Cosela (trilaciclib)
    7d
    Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=144, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial • Combination therapy • Metastases
    |
    paclitaxel • docetaxel • capecitabine • Kisqali (ribociclib)
    7d
    Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting | N=50 --> 10 | Trial completion date: Nov 2025 --> Jul 2026 | Trial primary completion date: Dec 2024 --> Feb 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    Verzenio (abemaciclib) • Nubeqa (darolutamide)
    8d
    NCI-2018-01050: Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=15, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2024 | Trial primary completion date: Dec 2025 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Ibrance (palbociclib) • letrozole • hydroxychloroquine
    9d
    CYCLONE 3: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (clinicaltrials.gov)
    P3, N=900, Active, not recruiting, Eli Lilly and Company | Trial primary completion date: Oct 2025 --> Feb 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    Verzenio (abemaciclib) • abiraterone acetate
    9d
    PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=73, Completed, SOLTI Breast Cancer Research Group | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    HER-2 positive • HR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • tamoxifen • Kadcyla (ado-trastuzumab emtansine) • capecitabine • fulvestrant • Halaven (eribulin mesylate) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    9d
    UCLA B-13: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Jonsson Comprehensive Cancer Center | Phase classification: P1b --> P1/2 | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 amplification
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Kisqali (ribociclib) • fulvestrant • Tukysa (tucatinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    9d
    TATEN: Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, SOLTI Breast Cancer Research Group | Trial completion date: Nov 2024 --> May 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HR positive • HER-2 negative • HER-2 expression • PGR expression
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • nCounter® Breast Cancer 360™ Panel
    |
    Keytruda (pembrolizumab) • paclitaxel
    9d
    BGB-43395-102: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=78, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    fulvestrant • letrozole
    10d
    the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Henan Cancer Hospital
    New P2 trial • Metastases
    |
    Cosela (trilaciclib)
    10d
    Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer. (PubMed, Breast Cancer Res Treat)
    Although grade 3-4 toxicity and dose reductions occurred frequently, most were expected and managed by dose reductions, showing that palbociclib is generally well tolerated and thus represents a valuable treatment option in the older population.
    Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib)
    11d
    Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation. (PubMed, Exp Mol Med)
    Inhibition of MAP3K3 decreased YAP-dependent cell proliferation and successfully restored BRAF inhibitor sensitivity. In conclusion, our study reveals a previously unrecognized mechanism for the regulation of YAP stability, suggesting MAP3K3 inhibition as a promising strategy for overcoming resistance to CDK4/6 and BRAF inhibitors in cancer treatment.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7)
    11d
    Targeting cellular senescence as a therapeutic vulnerability in gastric cancer. (PubMed, Life Sci)
    Overall, GSS offers a framework for better understanding of correlation between senescence and GC, which might provide new insights into the development of novel therapeutics in GC.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CCL2 (Chemokine (C-C motif) ligand 2) • CD96 (CD96 Molecule) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    Ibrance (palbociclib)
    11d
    Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study. (PubMed, JCO Glob Oncol)
    The high-quality evidence from the BrasiLEEira study corroborates the RCTs' findings, expanding its validity to a broader spectrum and underrepresented population who may benefit from ribociclib treatment.
    Clinical • Journal • HEOR • Real-world evidence • Real-world • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Kisqali (ribociclib)
    11d
    Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review. (PubMed, Breast Cancer (Dove Med Press))
    In this review, we generally summarize the mechanisms of resistance to CDK4/6is and ET, and describe the findings from clinical trials using small molecule inhibitors, antibody-drug conjugates and immunotherapy, providing insights into how these novel strategies may reverse treatment resistance, and discussing how some have not translated into clinical benefit. Finally, we provide rational treatment strategies based on the current emerging evidence.
    Review • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive
    11d
    Ring-contracted Artemisinin Derivatives as Novel CDK4/6 Inhibitors: Synthesis and Anti-Breast Cancer Evaluation. (PubMed, Chem Biodivers)
    In antiproliferative activities and kinase inhibitory effects assays, we found that the antiproliferative effects of B01 were close to positive controls Palbociclib, with GI50 values of 4.87±0.23 μM and 9.97±1.44 μM towards T47D cells and MDA-MB-436 cells respectively. In addition, the results showed that B01 were the most potent compounds against CDK6/cyclin D3 kinase, with IC50 values of 0.135±0.041 μM, its activity is about 1/3 of the positive control Palbociclib.
    Journal
    |
    CCND3 (Cyclin D3)
    |
    Ibrance (palbociclib)
    11d
    CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma. (PubMed, Sci Rep)
    We found that Trametinib has a lower IC50 than Gemcitabine in PDAC cell lines. The study shows Trametinib has a critical inhibitory effect on PDAC. Besides, the combination of Trametinib with Palbociclib can inhibit the proliferation of PDAC-resistant cells.
    Journal
    |
    IFNG (Interferon, gamma)
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • gemcitabine
    11d
    ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Dana-Farber Cancer Institute
    New P2 trial • Mismatch repair • Metastases
    |
    Keytruda (pembrolizumab) • Verzenio (abemaciclib) • letrozole
    11d
    Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P1/2 trial
    |
    PD-L1 expression
    |
    Ibrance (palbociclib) • Tevimbra (tislelizumab)
    12d
    An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. (clinicaltrials.gov)
    P3, N=210, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P3 trial • Metastases
    |
    cisplatin • gemcitabine • Tevimbra (tislelizumab) • Cosela (trilaciclib)
    14d
    Study of Ribociclib and Everolimus in HGG and DIPG (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Nationwide Children's Hospital | Trial completion date: Jan 2034 --> May 2034 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2028 --> May 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C)
    |
    PIK3CA mutation • PTEN mutation • CDKN2A deletion • PIK3CA amplification • CCND1 amplification • CDK4 amplification • PIK3R1 mutation
    |
    everolimus • Kisqali (ribociclib)
    15d
    Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial (clinicaltrials.gov)
    P2, N=32, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Metastases
    |
    Tagrisso (osimertinib) • AiRuiKang (dalpiciclib)
    15d
    A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, National Cancer Center, China
    New P1 trial • Combination therapy • Metastases
    |
    Tagrisso (osimertinib) • BPI-1178
    15d
    Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer. (PubMed, Semin Oncol)
    Palbociclib+letrozole was the most frequently prescribed treatment (36.8%). Most patients presented hematologic toxicity but to a low degree. The probability of survival increases with treatment.
    Journal • Real-world evidence • Real-world
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Ibrance (palbociclib) • letrozole
    15d
    Predicting drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning. (PubMed, Expert Opin Drug Metab Toxicol)
    This review provides key background information on the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Additionally, special consideration should be given to populations at higher risk for polypharmacy, such as older patients with greater comorbidities. These interactions and patient characteristics should be considered when developing individual treatment plans with CDK4/6 inhibitors.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
    15d
    IMPORTANT: Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (clinicaltrials.gov)
    P3, N=495, Recruiting, Region Örebro County | Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Mar 2024
    Enrollment open • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HR positive • HER-2 negative
    |
    fulvestrant
    16d
    Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials. (PubMed, Breast)
    New generation selective estrogen receptor degraders (SERDs), orally administered and with higher bioavailability, could potentially be the novel compounds to meet this emerging need. In this paper, we review accredited clinical studies on the combining effects of CDK4/6 inhibitors and oral SERDs, report efficacy of treatment data when available, and provide a framework for future research focusing on these promising agents.
    Review • Journal • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    16d
    Abemaciclib and Vacuolin-1 decrease aggregate-prone TDP-43 accumulation by accelerating autophagic flux. (PubMed, Biochem Biophys Rep)
    A treatment with the VPS34 inhibitor wortmannin (WM) suppressed Abe-/Vac-facilitated autophagic flux and the degradation of GFP-tagged aggregate-prone TDP-43. Collectively, these results suggest that Abe and Vac degrade aggregate-prone TDP-43 by accelerating autophagosome formation and autophagosome-lysosome fusion through the formation of PI(3)P.
    Journal
    |
    LAMP1 (Lysosomal Associated Membrane Protein 1) • TARDBP (TAR DNA Binding Protein) • TSG101 (Tumor Susceptibility 101)
    |
    LAMP1 expression
    |
    Verzenio (abemaciclib)
    16d
    Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov)
    P2, N=47, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Ibrance (palbociclib) • fulvestrant • letrozole
    16d
    Rainbow: Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib (clinicaltrials.gov)
    P3, N=1900, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Verzenio (abemaciclib)